pith. sign in

arxiv: 2207.09264 · v2 · submitted 2022-07-19 · 🧬 q-bio.QM

Flow Rate Independent Multiscale Liquid Biopsy for Precision Oncology

Jing Yan , Jie Wang , Robert Dallmann , Renquan Lu , J\'er\^ome Charmet This is my paper

Pith reviewed 2026-05-24 11:23 UTC · model grok-4.3

classification 🧬 q-bio.QM
keywords liquid biopsycirculating tumor cellsCTC capturemultiscale meshflow rate independentimmunoaffinity enrichmentcancer detection
0
0 comments X

The pith

A multiscale mesh device captures circulating tumor cells with constant efficiency above 75 percent across flow rates from 50 to 200 microliters per minute.

A machine-rendered reading of the paper's core claim, the machinery that carries it, and where it could break.

The paper aims to solve the low throughput, complexity, and limited follow-up options that limit most immunoaffinity liquid biopsies for circulating tumor cells. It does so by building a simple mesh device whose structure is tuned separately at the binding, flow-path, and overall-device levels. This separation lets the device maintain high capture performance no matter how fast blood flows through it. Tests on blood from 79 cancer patients and 20 healthy people showed 96 percent sensitivity and 100 percent specificity, plus the ability to run further tests for treatment decisions.

Core claim

By decoupling and independently optimizing the nano-, micro- and macro-scales of an enrichment device that is simple to fabricate and operate, the scalable mesh approach enables optimum capture conditions at any flow rate, demonstrated with constant capture efficiencies above 75 percent between 50-200 uL/min. The device detected CTCs with 96 percent sensitivity and 100 percent specificity in 79 cancer patients and 20 healthy controls and supports post-processing such as identifying responders to immune checkpoint inhibition and detecting HER2 positive breast cancer, with results that compare well with other assays including clinical standards.

What carries the argument

The scalable mesh approach that decouples and independently optimizes the nano-, micro-, and macro-scales of the enrichment device to maintain capture efficiency independent of flow rate.

If this is right

  • Higher sample volumes can be processed without loss of capture performance.
  • Post-processing steps remain compatible, allowing identification of therapy responders and specific markers such as HER2.
  • The method performs at levels comparable to existing clinical assays.
  • Fabrication and operation are simplified relative to other affinity-based devices.

Where Pith is reading between the lines

These are editorial extensions of the paper, not claims the author makes directly.

  • Flow-rate independence may allow the device to work with varying clinical equipment or sample volumes without recalibration.
  • The same mesh design principle could be tested on other rare cell types or biomarkers beyond tumor cells.
  • Larger or more varied patient groups would be needed to confirm whether the reported sensitivity and specificity hold outside the initial cohort.

Load-bearing premise

Tuning the binding sites, flow paths, and overall device size separately will keep capture rates steady no matter the speed of the blood flow, without hurting accuracy or later lab work.

What would settle it

An experiment that measures capture efficiency at several flow rates between 50 and 200 uL/min and finds the efficiency drops below 75 percent at any tested speed.

Figures

Figures reproduced from arXiv: 2207.09264 by J\'er\^ome Charmet, Jie Wang, Jing Yan, Renquan Lu, Robert Dallmann.

Figure 2
Figure 2. Figure 2: Flow rate independence. Panel (a) shows that capture efficiency can be kept constant (as confirmed by one-way ANOVA [F=0.37, p=0.05] and post-hoc Tukey’s test (Fig. S2)) as long as the velocity is kept constant. This is achieved by scaling the surface area by the same factor as the flow rate as given by v =αQ/αA. In comparison, one observes a significant capture efficiency decrease (one-way ANOVA [F=38.04,… view at source ↗
Figure 3
Figure 3. Figure 3: Comparative (semi-quantitative) multiphysics simulations. Panel (a) shows the effect of the flow rate on the capture of diluted species (arbitrary concentration C0 indicated in red) on the mesh. Here a cross section is represented. A depletion zone (blue) appears for a flow rate Q0 and decreases progressively as the flow rates are increased (2Q0 and 3 Q0). The same was observed for discrete events, [PITH_… view at source ↗
Figure 4
Figure 4. Figure 4: Nano-functionalization strategies and performance of the device. (a) the nanobranched sulfhydryl hyaluronic acid (HA-SH) synthesis steps. (b) the micrographs of MCF-7 cells on the mesh after being captured with different concentration (approximately 150, 100 and 50 cells per mL for l, ll and III respectively) with a scale bar of 200 µm. The effect of different meshes pore sizes (10x18, 15x20 and 20x20 µm) … view at source ↗
Figure 5
Figure 5. Figure 5: Clinical validation of the device on two cohorts, in three separate studies. The first study, shown in panel (a), with 79 cancer patients with a range of different cancer types and 20 healthy controls was used to characterize the performance of our device. CK+; DAPI+; CK- cells were identified as CTCs (inset), scale bar 20 µm. A subset of patients (n=33) from the initial cohort were selected to evaluate PD… view at source ↗
read the original abstract

Immunoaffinity-based liquid biopsies of circulating tumor cells (CTCs) hold great promise for cancer management, but typically suffer from low throughput, relative complexity and post-processing limitations. Here we address these issues simultaneously by decoupling and independently optimizing the nano-, micro- and macro-scales of an enrichment device that is simple to fabricate and operate. Unlike other affinity-based devices, our scalable mesh approach enables optimum capture conditions at any flow rate, as demonstrated with constant capture efficiencies, above 75% between 50-200 uL/min. The device achieved 96% sensitivity and 100% specificity when used to detect CTCs in the blood of 79 cancer patients and 20 healthy controls. We demonstrate its post processing capacity with the identification of potential responders to immune checkpoint inhibition therapy and the detection of HER2 positive breast cancer. The results compare well with other assays, including clinical standards. This suggests that our approach, which overcomes major limitations associated with affinity-based liquid biopsies, could help improve cancer management.

Editorial analysis

A structured set of objections, weighed in public.

Desk editor's note, referee report, simulated authors' rebuttal, and a circularity audit. Tearing a paper down is the easy half of reading it; the pith above is the substance, this is the friction.

Referee Report

2 major / 1 minor

Summary. The manuscript describes a multiscale mesh-based immunoaffinity device for CTC enrichment that decouples and independently optimizes nano-, micro-, and macro-scales to achieve flow-rate-independent capture. It reports constant efficiencies above 75% across 50-200 µL/min, 96% sensitivity and 100% specificity on 79 cancer patients and 20 healthy controls, plus post-processing applications for immune checkpoint response prediction and HER2 detection, claiming advantages over existing affinity-based liquid biopsies.

Significance. If the flow-rate independence and clinical metrics are substantiated with full methods and mechanistic support, the approach could meaningfully improve CTC liquid biopsy throughput and operational simplicity, addressing key limitations of current affinity devices while maintaining compatibility with downstream analyses.

major comments (2)
  1. [Abstract] Abstract: The central claim that independent optimization of the three scales produces optimum capture conditions at any flow rate (constant efficiency >75% from 50-200 µL/min) is presented without any design rules, equations, or optimization framework that maps nano-scale antibody density, micro-scale mesh geometry, and macro-scale device dimensions onto a flow-rate-independent capture probability. The text proceeds directly from the assertion of scale decoupling to the empirical flat efficiency curve, leaving the mechanistic basis for generality unaddressed.
  2. [Abstract] Abstract (performance metrics): The reported 96% sensitivity and 100% specificity are stated without error bars, patient cohort stratification details, or direct head-to-head comparison data against clinical standards within the provided text; this weakens the claim that results 'compare well with other assays' and requires the full methods and results sections to verify load-bearing clinical performance.
minor comments (1)
  1. [Abstract] Abstract: Units are written as 'uL/min' rather than the conventional 'µL/min'.

Simulated Author's Rebuttal

2 responses · 0 unresolved

We thank the referee for their constructive comments on our manuscript. We address each major comment point by point below, providing clarifications from the full text and indicating revisions where they strengthen the presentation without altering the core findings.

read point-by-point responses

  1. Referee: [Abstract] Abstract: The central claim that independent optimization of the three scales produces optimum capture conditions at any flow rate (constant efficiency >75% from 50-200 µL/min) is presented without any design rules, equations, or optimization framework that maps nano-scale antibody density, micro-scale mesh geometry, and macro-scale device dimensions onto a flow-rate-independent capture probability. The text proceeds directly from the assertion of scale decoupling to the empirical flat efficiency curve, leaving the mechanistic basis for generality unaddressed.

    Authors: The abstract is intentionally concise. The full manuscript (Methods and Results sections) details the multiscale optimization framework, including how nano-scale antibody density, micro-scale mesh geometry parameters, and macro-scale device dimensions are independently tuned to yield flow-rate-independent capture probability. Supporting equations, design rules, and mechanistic rationale for the observed flat efficiency curve (constant >75% from 50-200 µL/min) are provided there, along with experimental validation. We will revise the abstract to include a brief clause referencing this optimization framework and its role in achieving generality. revision: yes

  2. Referee: [Abstract] Abstract (performance metrics): The reported 96% sensitivity and 100% specificity are stated without error bars, patient cohort stratification details, or direct head-to-head comparison data against clinical standards within the provided text; this weakens the claim that results 'compare well with other assays' and requires the full methods and results sections to verify load-bearing clinical performance.

    Authors: The abstract summarizes the primary clinical metrics from the 79-patient/20-control cohort. Full details—including error bars or confidence intervals, cohort stratification by cancer type/stage, and comparisons to literature values for other assays and clinical standards—are reported in the Results and Discussion sections. The claim of comparing well is based on those data. We will revise the abstract to note the cohort size and indicate that detailed verification appears in the main text, while preserving abstract length constraints. revision: partial

Circularity Check

0 steps flagged

No circularity; purely experimental results with no derivation chain

full rationale

The paper reports direct experimental measurements of capture efficiency across flow rates and clinical performance metrics from patient samples. No equations, models, predictions, or first-principles derivations are present that could reduce to fitted inputs or self-referential definitions. The multiscale optimization is asserted as a design premise but is not linked to any mathematical framework whose output would be forced by its own inputs. Self-citations, if present, are not load-bearing for any claimed result. The work is therefore self-contained against external benchmarks via empirical validation.

Axiom & Free-Parameter Ledger

0 free parameters · 0 axioms · 0 invented entities

The central claim rests on empirical performance data from clinical samples rather than theoretical axioms or new physical entities; no free parameters or invented entities are introduced.

pith-pipeline@v0.9.0 · 5716 in / 1122 out tokens · 25165 ms · 2026-05-24T11:23:58.423966+00:00 · methodology

discussion (0)

Sign in with ORCID, Apple, or X to comment. Anyone can read and Pith papers without signing in.

Reference graph

Works this paper leans on

54 extracted references · 54 canonical work pages

  1. [1]

    Liquid biopsy and minimal residual disease — latest advances and implications for cure,

    K. Pantel and C. Alix-Panabières, “Liquid biopsy and minimal residual disease — latest advances and implications for cure,” Nat Rev Clin Oncol, vol. 16, no. 7, pp. 409–424, Jul. 2019, doi: 10.1038/s41571-019-0187-3

    work page doi:10.1038/s41571-019-0187-3 2019

  2. [2]

    Microfluidics and cancer analysis: cell separation, cell/tissue culture, cell mechanics, and integrated analysis systems,

    D. Pappas, “Microfluidics and cancer analysis: cell separation, cell/tissue culture, cell mechanics, and integrated analysis systems,” Analyst, vol. 141, no. 2, pp. 525–535, 2016, doi: 10.1039/C5AN01778E

    work page doi:10.1039/c5an01778e 2016

  3. [3]

    Cancer diagnosis: from tumor to liquid biopsy and beyond,

    R. Vaidyanathan, R. Hao Soon, P. Zhang, K. Jiang, and C. Teck Lim, “Cancer diagnosis: from tumor to liquid biopsy and beyond,” Lab on a Chip, vol. 19, no. 1, pp. 11–34, 2019, doi: 10.1039/C8LC00684A

    work page doi:10.1039/c8lc00684a 2019

  4. [4]

    Circulating extracellular vesicles are effective biomarkers for predicting response to cancer therapy,

    E. Zhou et al., “Circulating extracellular vesicles are effective biomarkers for predicting response to cancer therapy,” EBioMedicine, vol. 67, p. 103365, May 2021, doi: 10.1016/j.ebiom.2021.103365

    work page doi:10.1016/j.ebiom.2021.103365 2021

  5. [5]

    Tumor Self-Seeding by Circulating Cancer Cells,

    M.-Y. Kim et al., “Tumor Self-Seeding by Circulating Cancer Cells,” Cell, vol. 139, no. 7, pp. 1315–1326, Dec. 2009, doi: 10.1016/j.cell.2009.11.025

    work page doi:10.1016/j.cell.2009.11.025 2009

  6. [6]

    Evaluation and Prognostic Significance of Circulating Tumor Cells in Patients With Non-Small-Cell Lung Cancer,

    M. Krebs et al., “Evaluation and Prognostic Significance of Circulating Tumor Cells in Patients With Non-Small-Cell Lung Cancer,” Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol. 29, pp. 1556–63, Mar. 2011, doi: 10.1200/JCO.2010.28.7045

    work page doi:10.1200/jco.2010.28.7045 2011

  7. [7]

    Capture of Viable Circulating Tumor Cells in the Liver of Colorectal Cancer Patients,

    E. Denève et al., “Capture of Viable Circulating Tumor Cells in the Liver of Colorectal Cancer Patients,” Clinical Chemistry, vol. 59, no. 9, pp. 1384–1392, Sep. 2013, doi: 10.1373/clinchem.2013.202846

    work page doi:10.1373/clinchem.2013.202846 2013

  8. [8]

    Circulating tumor cells in clinical research and monitoring patients with colorectal cancer,

    C. Burz et al., “Circulating tumor cells in clinical research and monitoring patients with colorectal cancer,” Oncotarget, vol. 9, no. 36, pp. 24561–24571, May 2018, doi: 10.18632/oncotarget.25337

    work page doi:10.18632/oncotarget.25337 2018

  9. [9]

    Functional analysis of circulating tumour cells: the KEY to understand the biology of the metastatic cascade,

    Z. Eslami-S, L. E. Cortés-Hernández, F. Thomas, K. Pantel, and C. Alix-Panabières, “Functional analysis of circulating tumour cells: the KEY to understand the biology of the metastatic cascade,” Br J Cancer, pp. 1–11, Apr. 2022, doi: 10.1038/s41416-022-01819-1

    work page doi:10.1038/s41416-022-01819-1 2022

  10. [10]

    Circulating tumor cell technologies,

    M. M. Ferreira, V. C. Ramani, and S. S. Jeffrey, “Circulating tumor cell technologies,” Molecular Oncology, vol. 10, no. 3, pp. 374–394, Mar. 2016, doi: 10.1016/j.molonc.2016.01.007

    work page doi:10.1016/j.molonc.2016.01.007 2016

  11. [11]

    Isolation of rare circulating tumour cells in cancer patients by microchip technology,

    S. Nagrath et al., “Isolation of rare circulating tumour cells in cancer patients by microchip technology,” Nature, vol. 450, no. 7173, pp. 1235–1239, Dec. 2007, doi: 10.1038/nature06385

    work page doi:10.1038/nature06385 2007

  12. [12]

    Diagnostic leukapheresis enables reliable detection of circulating tumor cells of nonmetastatic cancer patients,

    J. C. Fischer et al., “Diagnostic leukapheresis enables reliable detection of circulating tumor cells of nonmetastatic cancer patients,” PNAS, vol. 110, no. 41, pp. 16580–16585, Oct. 2013, doi: 10.1073/pnas.1313594110

    work page doi:10.1073/pnas.1313594110 2013

  13. [13]

    Tumor Cells Circulate in the Peripheral Blood of All Major Carcinomas but not in Healthy Subjects or Patients With Nonmalignant Diseases,

    W. J. Allard et al., “Tumor Cells Circulate in the Peripheral Blood of All Major Carcinomas but not in Healthy Subjects or Patients With Nonmalignant Diseases,” Clin Cancer Res, vol. 10, no. 20, pp. 6897–6904, Oct. 2004, doi: 10.1158/1078-0432.CCR-04-0378

    work page doi:10.1158/1078-0432.ccr-04-0378 2004

  14. [14]

    Subclassification of prostate cancer circulating tumor cells by nuclear size reveals very small nuclear circulating tumor cells in patients with visceral metastases,

    J.-F. Chen et al., “Subclassification of prostate cancer circulating tumor cells by nuclear size reveals very small nuclear circulating tumor cells in patients with visceral metastases,” Cancer, vol. 121, no. 18, pp. 3240–3251, 2015, doi: 10.1002/cncr.29455

    work page doi:10.1002/cncr.29455 2015

  15. [15]

    Isolation, Detection, and Antigen-Based Profiling of Circulating Tumor Cells Using a Size-Dictated Immunocapture Chip,

    M. G. Ahmed et al., “Isolation, Detection, and Antigen-Based Profiling of Circulating Tumor Cells Using a Size-Dictated Immunocapture Chip,” Angewandte Chemie International Edition, vol. 56, no. 36, pp. 10681–10685, 2017, doi: 10.1002/anie.201702675

    work page doi:10.1002/anie.201702675 2017

  16. [16]

    Microfluidic, marker-free isolation of circulating tumor cells from blood samples,

    N. M. Karabacak et al., “Microfluidic, marker-free isolation of circulating tumor cells from blood samples,” Nat Protoc, vol. 9, no. 3, Art. no. 3, Mar. 2014, doi: 10.1038/nprot.2014.044

    work page doi:10.1038/nprot.2014.044 2014

  17. [17]

    Single-Cell Phenotypic Profiling of CTCs in Whole Blood Using an Integrated Microfluidic Device,

    H. Pei et al., “Single-Cell Phenotypic Profiling of CTCs in Whole Blood Using an Integrated Microfluidic Device,” Anal. Chem., vol. 91, no. 17, pp. 11078–11084, Sep. 2019, doi: 10.1021/acs.analchem.9b01647. 17

    work page doi:10.1021/acs.analchem.9b01647 2019

  18. [18]

    Ultrahigh-throughput magnetic sorting of large blood volumes for epitope- agnostic isolation of circulating tumor cells,

    A. Mishra et al., “Ultrahigh-throughput magnetic sorting of large blood volumes for epitope- agnostic isolation of circulating tumor cells,” Proceedings of the National Academy of Sciences, vol. 117, no. 29, pp. 16839–16847, Jul. 2020, doi: 10.1073/pnas.2006388117

    work page doi:10.1073/pnas.2006388117 2020

  19. [19]

    Microfluidic Screening of Circulating Tumor Biomarkers toward Liquid Biopsy,

    N. Hao and J. X. J. Zhang, “Microfluidic Screening of Circulating Tumor Biomarkers toward Liquid Biopsy,” Separation & Purification Reviews, vol. 47, no. 1, pp. 19–48, Jan. 2018, doi: 10.1080/15422119.2017.1320763

    work page doi:10.1080/15422119.2017.1320763 2018

  20. [20]

    Circulating Tumor Cells: Liquid Biopsy of Cancer,

    C. Alix-Panabières and K. Pantel, “Circulating Tumor Cells: Liquid Biopsy of Cancer,” Clinical Chemistry, vol. 59, no. 1, pp. 110–118, Jan. 2013, doi: 10.1373/clinchem.2012.194258

    work page doi:10.1373/clinchem.2012.194258 2013

  21. [21]

    Microfluidics for Liquid Biopsies: Recent Advances, Current Challenges, and Future Directions,

    Y. Belotti and C. T. Lim, “Microfluidics for Liquid Biopsies: Recent Advances, Current Challenges, and Future Directions,” Anal. Chem., vol. 93, no. 11, pp. 4727–4738, Mar. 2021, doi: 10.1021/acs.analchem.1c00410

    work page doi:10.1021/acs.analchem.1c00410 2021

  22. [22]

    Specific Capture and Release of Circulating Tumor Cells Using Aptamer- Modified Nanosubstrates,

    Q. Shen et al., “Specific Capture and Release of Circulating Tumor Cells Using Aptamer- Modified Nanosubstrates,” Advanced Materials, vol. 25, no. 16, pp. 2368–2373, 2013, doi: 10.1002/adma.201300082

    work page doi:10.1002/adma.201300082 2013

  23. [23]

    NanoVelcro Chip for CTC enumeration in prostate cancer patients,

    Y.-T. Lu et al., “NanoVelcro Chip for CTC enumeration in prostate cancer patients,” Methods, vol. 64, no. 2, pp. 144–152, Dec. 2013, doi: 10.1016/j.ymeth.2013.06.019

    work page doi:10.1016/j.ymeth.2013.06.019 2013

  24. [24]

    System Modularity Chip for Analysis of Rare Targets (SMART-Chip): Liquid Biopsy Samples,

    T. N. Pahattuge et al., “System Modularity Chip for Analysis of Rare Targets (SMART-Chip): Liquid Biopsy Samples,” ACS Sens., vol. 6, no. 5, pp. 1831–1839, May 2021, doi: 10.1021/acssensors.0c02728

    work page doi:10.1021/acssensors.0c02728 2021

  25. [25]

    Highly Efficient Capture of Circulating Tumor Cells by Using Nanostructured Silicon Substrates with Integrated Chaotic Micromixers,

    S. Wang et al., “Highly Efficient Capture of Circulating Tumor Cells by Using Nanostructured Silicon Substrates with Integrated Chaotic Micromixers,” Angewandte Chemie, vol. 123, no. 13, pp. 3140–3144, 2011, doi: 10.1002/ange.201005853

    work page doi:10.1002/ange.201005853 2011

  26. [26]

    Enhanced Isolation and Release of Circulating Tumor Cells Using Nanoparticle Binding and Ligand Exchange in a Microfluidic Chip,

    M.-H. Park et al., “Enhanced Isolation and Release of Circulating Tumor Cells Using Nanoparticle Binding and Ligand Exchange in a Microfluidic Chip,” ACS Publications, Feb. 09, 2017. https://pubs.acs.org/doi/pdf/10.1021/jacs.6b12236 (accessed Dec. 31, 2021)

    work page doi:10.1021/jacs.6b12236 2017

  27. [27]

    Making it stick: convection, reaction and diffusion in surface-based biosensors,

    T. M. Squires, R. J. Messinger, and S. R. Manalis, “Making it stick: convection, reaction and diffusion in surface-based biosensors,” Nat Biotechnol, vol. 26, no. 4, pp. 417–426, Apr. 2008, doi: 10.1038/nbt1388

    work page doi:10.1038/nbt1388 2008

  28. [28]

    Shake It or Shrink It: Mass Transport and Kinetics in Surface Bioassays Using Agitation and Microfluidics,

    I. Pereiro, A. Fomitcheva-Khartchenko, and G. V. Kaigala, “Shake It or Shrink It: Mass Transport and Kinetics in Surface Bioassays Using Agitation and Microfluidics,” Analytical Chemistry, Jun. 2020, doi: 10.1021/acs.analchem.0c01625

    work page doi:10.1021/acs.analchem.0c01625 2020

  29. [29]

    Transient Convection, Diffusion, and Adsorption in Surface-Based Biosensors,

    R. Hansen, H. Bruus, T. H. Callisen, and O. Hassager, “Transient Convection, Diffusion, and Adsorption in Surface-Based Biosensors,” Langmuir, vol. 28, no. 19, pp. 7557–7563, May 2012, doi: 10.1021/la3000763

    work page doi:10.1021/la3000763 2012

  30. [30]

    General model for mass transport to planar and nanowire biosensor surfaces,

    D. S. Jin, E. L. Brightbill, and E. M. Vogel, “General model for mass transport to planar and nanowire biosensor surfaces,” Journal of Applied Physics, vol. 125, no. 11, p. 114502, Mar. 2019, doi: 10.1063/1.5084253

    work page doi:10.1063/1.5084253 2019

  31. [31]

    EpCAM: Structure and function in health and disease,

    U. Schnell, V. Cirulli, and B. N. G. Giepmans, “EpCAM: Structure and function in health and disease,” Biochimica et Biophysica Acta (BBA) - Biomembranes, vol. 1828, no. 8, pp. 1989–2001, Aug. 2013, doi: 10.1016/j.bbamem.2013.04.018

    work page doi:10.1016/j.bbamem.2013.04.018 1989

  32. [32]

    Combined use of EpCAM and FRα enables the high-efficiency capture of circulating tumor cells in non-small cell lung cancer,

    L. Chen et al., “Combined use of EpCAM and FRα enables the high-efficiency capture of circulating tumor cells in non-small cell lung cancer,” Sci Rep, vol. 8, no. 1, p. 1188, Jan. 2018, doi: 10.1038/s41598-018-19391-1

    work page doi:10.1038/s41598-018-19391-1 2018

  33. [33]

    The detection of EpCAM+ and EpCAM– circulating tumor cells,

    S. de Wit et al., “The detection of EpCAM+ and EpCAM– circulating tumor cells,” Sci Rep, vol. 5, no. 1, p. 12270, Jul. 2015, doi: 10.1038/srep12270

    work page doi:10.1038/srep12270 2015

  34. [34]

    Engineered Alginate Hydrogels for Effective Microfluidic Capture and Release of Endothelial Progenitor Cells from Whole Blood,

    A. Hatch, G. Hansmann, and S. K. Murthy, “Engineered Alginate Hydrogels for Effective Microfluidic Capture and Release of Endothelial Progenitor Cells from Whole Blood,” Langmuir, vol. 27, no. 7, pp. 4257–4264, Apr. 2011, doi: 10.1021/la105016a. 18

    work page doi:10.1021/la105016a 2011

  35. [35]

    Biopolymer System for Cell Recovery from Microfluidic Cell Capture Devices,

    A. M. Shah et al., “Biopolymer System for Cell Recovery from Microfluidic Cell Capture Devices,” Anal. Chem., vol. 84, no. 8, pp. 3682–3688, Apr. 2012, doi: 10.1021/ac300190j

    work page doi:10.1021/ac300190j 2012

  36. [36]

    The role of polymers in detection and isolation of circulating tumor cells,

    J. Hye Myung, K. A. Gajjar, Y. Eon Han, and S. Hong, “The role of polymers in detection and isolation of circulating tumor cells,” Polymer Chemistry, vol. 3, no. 9, pp. 2336–2341, 2012, doi: 10.1039/C2PY20420G

    work page doi:10.1039/c2py20420g 2012

  37. [37]

    Emerging microfluidic devices for cancer cells/biomarkers manipulation and detection,

    V. H. Perez-Gonzalez, R. C. Gallo-Villanueva, S. Camacho-Leon, J. I. Gomez-Quiñones, J. M. Rodriguez-Delgado, and S. O. Martinez-Chapa, “Emerging microfluidic devices for cancer cells/biomarkers manipulation and detection,” IET Nanobiotechnology, vol. 10, no. 5, pp. 263–275, 2016, doi: 10.1049/iet-nbt.2015.0060

    work page doi:10.1049/iet-nbt.2015.0060 2016

  38. [38]

    Continuous flow microfluidic separation and processing of rare cells and bioparticles found in blood – A review,

    M. Antfolk and T. Laurell, “Continuous flow microfluidic separation and processing of rare cells and bioparticles found in blood – A review,” Analytica Chimica Acta, vol. 965, pp. 9–35, May 2017, doi: 10.1016/j.aca.2017.02.017

    work page doi:10.1016/j.aca.2017.02.017 2017

  39. [39]

    3D microfilter device for viable circulating tumor cell (CTC) enrichment from blood,

    S. Zheng et al., “3D microfilter device for viable circulating tumor cell (CTC) enrichment from blood,” Biomed Microdevices, vol. 13, no. 1, pp. 203–213, Feb. 2011, doi: 10.1007/s10544-010-9485-3

    work page doi:10.1007/s10544-010-9485-3 2011

  40. [40]

    Filter Characteristics Influencing Circulating Tumor Cell Enrichment from Whole Blood,

    F. A. W. Coumans, G. van Dalum, M. Beck, and L. W. M. M. Terstappen, “Filter Characteristics Influencing Circulating Tumor Cell Enrichment from Whole Blood,” PLOS ONE, vol. 8, no. 4, p. e61770, avr 2013, doi: 10.1371/journal.pone.0061770

    work page doi:10.1371/journal.pone.0061770 2013

  41. [41]

    Microfluidic analysis of circulating tumor cells and tumor-derived extracellular vesicles,

    F. Tian, C. Liu, L. Lin, Q. Chen, and J. Sun, “Microfluidic analysis of circulating tumor cells and tumor-derived extracellular vesicles,” TrAC Trends in Analytical Chemistry, vol. 117, pp. 128–145, Aug. 2019, doi: 10.1016/j.trac.2019.05.013

    work page doi:10.1016/j.trac.2019.05.013 2019

  42. [42]

    Detachment strategies for affinity-adsorbed cells,

    X. Cao, R. Eisenthal, and J. Hubble, “Detachment strategies for affinity-adsorbed cells,” Enzyme and Microbial Technology, vol. 31, no. 1, pp. 153–160, Jul. 2002, doi: 10.1016/S0141-0229(02)00083- 2

    work page doi:10.1016/s0141-0229(02)00083- 2002

  43. [43]

    Evaluation of PD-L1 expression on vortex-isolated circulating tumor cells in metastatic lung cancer,

    M. Dhar et al., “Evaluation of PD-L1 expression on vortex-isolated circulating tumor cells in metastatic lung cancer,” Sci Rep, vol. 8, no. 1, p. 2592, Feb. 2018, doi: 10.1038/s41598-018-19245-w

    work page doi:10.1038/s41598-018-19245-w 2018

  44. [44]

    Circulating Tumor Cell PD-L1 Expression as Biomarker for Therapeutic Efficacy of Immune Checkpoint Inhibition in NSCLC,

    V. Kloten, R. Lampignano, T. Krahn, and T. Schlange, “Circulating Tumor Cell PD-L1 Expression as Biomarker for Therapeutic Efficacy of Immune Checkpoint Inhibition in NSCLC,” Cells, vol. 8, no. 8, Art. no. 8, Aug. 2019, doi: 10.3390/cells8080809

    work page doi:10.3390/cells8080809 2019

  45. [45]

    PD-L1 expressing circulating tumour cells in head and neck cancers,

    A. Kulasinghe, C. Perry, L. Kenny, M. E. Warkiani, C. Nelson, and C. Punyadeera, “PD-L1 expressing circulating tumour cells in head and neck cancers,” BMC Cancer, vol. 17, no. 1, p. 333, May 2017, doi: 10.1186/s12885-017-3316-3

    work page doi:10.1186/s12885-017-3316-3 2017

  46. [46]

    Determination of PD-L1 Expression in Circulating Tumor Cells of NSCLC Patients and Correlation with Response to PD-1/PD-L1 Inhibitors,

    M. Janning et al., “Determination of PD-L1 Expression in Circulating Tumor Cells of NSCLC Patients and Correlation with Response to PD-1/PD-L1 Inhibitors,” Cancers, vol. 11, no. 6, Art. no. 6, Jun. 2019, doi: 10.3390/cancers11060835

    work page doi:10.3390/cancers11060835 2019

  47. [47]

    HER2-family signalling mechanisms, clinical implications and targeting in breast cancer,

    N. Elster, D. M. Collins, S. Toomey, J. Crown, A. J. Eustace, and B. T. Hennessy, “HER2-family signalling mechanisms, clinical implications and targeting in breast cancer,” Breast Cancer Res Treat, vol. 149, no. 1, pp. 5–15, Jan. 2015, doi: 10.1007/s10549-014-3250-x

    work page doi:10.1007/s10549-014-3250-x 2015

  48. [48]

    HER2-targeted therapies — a role beyond breast cancer,

    D.-Y. Oh and Y.-J. Bang, “HER2-targeted therapies — a role beyond breast cancer,” Nat Rev Clin Oncol, vol. 17, no. 1, pp. 33–48, Jan. 2020, doi: 10.1038/s41571-019-0268-3

    work page doi:10.1038/s41571-019-0268-3 2020

  49. [49]

    HER2 status in breast cancer: changes in guidelines and complicating factors for interpretation,

    S. Ahn, J. W. Woo, K. Lee, and S. Y. Park, “HER2 status in breast cancer: changes in guidelines and complicating factors for interpretation,” J Pathol Transl Med, vol. 54, no. 1, pp. 34–44, Jan. 2020, doi: 10.4132/jptm.2019.11.03

    work page doi:10.4132/jptm.2019.11.03 2020

  50. [50]

    HER2-Positive Circulating Tumor Cells Indicate Poor Clinical Outcome in Stage I to III Breast Cancer Patients,

    P. Wülfing et al., “HER2-Positive Circulating Tumor Cells Indicate Poor Clinical Outcome in Stage I to III Breast Cancer Patients,” Clin Cancer Res, vol. 12, no. 6, pp. 1715–1720, Mar. 2006, doi: 10.1158/1078-0432.CCR-05-2087

    work page doi:10.1158/1078-0432.ccr-05-2087 2006

  51. [51]

    Highly sensitive enumeration of circulating tumor cells in lung cancer patients using a size-based filtration microfluidic chip,

    T. Huang et al., “Highly sensitive enumeration of circulating tumor cells in lung cancer patients using a size-based filtration microfluidic chip,” Biosensors and Bioelectronics, vol. 51, pp. 213–218, Jan. 2014, doi: 10.1016/j.bios.2013.07.044. 19

    work page doi:10.1016/j.bios.2013.07.044 2014

  52. [52]

    Multivalent Binding and Biomimetic Cell Rolling Improves the Sensitivity and Specificity of Circulating Tumor Cell Capture,

    J. H. Myung et al., “Multivalent Binding and Biomimetic Cell Rolling Improves the Sensitivity and Specificity of Circulating Tumor Cell Capture,” Clin Cancer Res, vol. 24, no. 11, pp. 2539–2547, Jun. 2018, doi: 10.1158/1078-0432.CCR-17-3078

    work page doi:10.1158/1078-0432.ccr-17-3078 2018

  53. [53]

    Dosing time dependent in vitro pharmacodynamics of Everolimus despite a defective circadian clock,

    Y. Zhang et al., “Dosing time dependent in vitro pharmacodynamics of Everolimus despite a defective circadian clock,” Cell Cycle, vol. 17, no. 1, pp. 33–42, Jan. 2018, doi: 10.1080/15384101.2017.1387695

    work page doi:10.1080/15384101.2017.1387695 2018

  54. [54]

    Transport and Adsorption,

    “Transport and Adsorption,” COMSOL. https://www.comsol.com/model/transport-and- adsorption-5 (accessed Dec. 31, 2021). Acknowledgements JC would like to acknowledge funding from the Newton Fund—Institutional Links grant (ID 352360246), and Engineering and Physical Sciences Research Council grant EPSRC EP/R00403X/1. We are grateful to Hannah Bridgewater fo...

    work page 2021